Our production technology is based on recombinant proteins and does not involve potential risk of pathogen contamination in any part of the production process or the distribution and handling of the vaccines and diagnostics.
Our products are supplied in lyophilized form which entirely avoids the need for refrigeration and continuous chain of refrigeration which constitutes a major problem in distribution, particularly in developing countries.
Ongoing stability experiments have shown that the integrity and antigenicity of our products in lyophilized extracts were not significantly affected by storage for more than 2 years. These results are encouraging since proteins in complex extracts are commonly exposed to proteolytic degradation by cellular proteases in the preparation.
Extended stability would favor production and storage of the antigen as well as handling of the recombinant immunogen during vaccine manufacturing and distribution.
|
